Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia
Evidence-based clinical practice guideline

Lise M. Bjerre MD PhD CCFP  Barbara Farrell PharmD ACPR FCSHP  Matthew Hogel PhD  Lyla Graham MD
Geneviève Lemay MD MSC FRCP  Lisa McCarthy PharmD MSC  Lalitha Raman-Wilms PharmD FCSHP
Carlos Rojas-Fernandez PharmD  Samir Sinha MD DPhil FRCP  Wade Thompson Rph MSC  Vivian Welch PhD  Andrew Wiens MD

Abstract

Objective To develop an evidence-based guideline to help clinicians make decisions about when and how to safely taper and stop antipsychotics; to focus on the highest level of evidence available and seek input from primary care professionals in the guideline development, review, and endorsement processes.

Methods The overall team comprised 9 clinicians (1 family physician, 1 family physician specializing in long-term care, 1 geriatric psychiatrist, 2 geriatricians, 4 pharmacists) and a methodologist; members disclosed conflicts of interest. For guideline development, a systematic process was used, including the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach. Evidence was generated from a Cochrane systematic review of antipsychotic deprescribing trials for the behavioural and psychological symptoms of dementia, and a systematic review was conducted to assess the evidence behind the benefits of using antipsychotics for insomnia. A review of reviews of the harms of continued antipsychotic use was performed, as well as narrative syntheses of patient preferences and resource implications. This evidence and GRADE quality-of-evidence ratings were used to generate recommendations. The team refined guideline content and recommendation wording through consensus and synthesized clinical considerations to address common front-line clinician questions. The draft guideline was distributed to clinicians and stakeholders for review and revisions were made at each stage.

Recommendations We recommend deprescribing antipsychotics for adults with behavioural and psychological symptoms of dementia treated for at least 3 months (symptoms stabilized or no response to an adequate trial) and for adults with primary insomnia treated for any duration or secondary insomnia in which underlying comorbidities are managed. A decision-support algorithm was developed to accompany the guideline.

Conclusion Antipsychotics are associated with harms and can be safely tapered. Patients and caregivers might be more amenable to deprescribing if they understand the rationale (potential for harm), are involved in developing the tapering plan, and are offered behavioural advice or management. This guideline provides recommendations for making decisions about when and how to reduce the dose of or stop antipsychotics. Recommendations are meant to assist with, not dictate, decision making in conjunction with patients and families.

Editor’s key points

- Antipsychotics are frequently used to control behavioural and psychological symptoms of dementia (BPSD) and for the treatment of insomnia.
- Antipsychotics have the potential for considerable harm, including an increased overall risk of death, cerebrovascular adverse events, extrapyramidal symptoms, gait disturbances and falls, somnolence, edema, urinary tract infections, weight gain, and diabetes; the risk of harm is higher with prolonged use and in the elderly.
- A systematic review of antipsychotic deprescribing (dose reduction or discontinuation) in patients taking them to control BPSD failed to demonstrate negative outcomes resulting from deprescribing.
- The evidence in support of the effectiveness of atypical antipsychotics for insomnia is poor and of low quality.
- This guideline recommends deprescribing antipsychotics in elderly patients taking them for insomnia and in adults who have had an adequate trial for BPSD (ie, behaviour stabilized for 3 months or unresponsive to treatment).
Deprescribing is the planned and supervised process of dose reduction or stopping of medication that might be causing harm or that might no longer be providing benefit. The goal of deprescribing is to reduce medication burden and harm while maintaining or improving quality of life. However, deprescribing can be difficult, especially when medications do not appear to be causing overt harm. In an effort to provide evidence-based recommendations and tools to aid clinicians in reducing or stopping medications that might no longer be needed or that might be causing harm, we initiated the Deprescribing Guidelines in the Elderly project (www.open-pharmacy-research.ca/research-projects/emerging-services/deprescribing-guidelines).

In a national modified Delphi consensus process, antipsychotics were selected as a high priority for deprescribing guideline development owing to their risk of harm and high prevalence of use. Antipsychotics are commonly used in the elderly, particularly in those residing in long-term care (LTC) facilities, to control certain behavioural and psychological symptoms of dementia (BPSD) including delusions, hallucinations, aggression, and agitation when there is potential for harm to the patient or others. A 2014 meta-analysis demonstrated statistically significant improvements in symptoms of BPSD as measured using 5 different scales for patients taking atypical antipsychotics compared with placebo. However, antipsychotic treatment initiated for BPSD is often continued chronically, despite a lack of documented ongoing indications for many patients. Because behavioural features of dementia change over time as the disease progresses, it is important to reassess the continued need for treatment.

In addition to their use for treating BPSD, atypical antipsychotics such as quetiapine are increasingly being used for their sedating properties in the treatment of insomnia. Prescriptions of quetiapine issued in Canada for sleep disturbances increased 10-fold in the 7-year period between 2005 and 2012. Antipsychotics have been associated with numerous side effects, the most severe of which are increased overall risk of death and increased risk of cerebrovascular adverse events. Atypical antipsychotics can cause weight gain and precipitate or worsen diabetes. While the absolute risk of some of these events is small, older people are often at higher risk of these outcomes. When antipsychotics are inappropriately prescribed or used for extended periods, they might contribute to polypharmacy, with its attendant risks of nonadherence, prescribing cascades, adverse reactions, medication errors, drug interactions, emergency department visits, and hospitalizations.

Overuse of antipsychotics in the elderly has been a growing concern. A total of $75 million was spent on antipsychotic prescriptions dispensed to elderly patients in Canada in the second quarter of 2014, representing an increase in prescriptions of 32% in a 4-year span. In terms of volume, 22.4% of residents in Canadian LTC homes in 2014 were taking antipsychotics chronically. Our primary target audience includes Canadian primary care and LTC physicians, pharmacists, nurse practitioners, and specialists who care for patients taking antipsychotics.

Our target patient population includes elderly patients taking antipsychotics for the purpose of treating BPSD, for treating primary insomnia, or for treating secondary insomnia when the underlying comorbidities are managed. This guideline does not apply to those taking antipsychotics for the treatment of schizophrenia, schizoaffective disorder, bipolar disorder, acute delirium, Tourette syndrome or tic disorders, autism, mental retardation or developmental delay, obsessive-compulsive disorder, alcoholism, cocaine abuse, or Parkinson disease psychosis; to those taking them as an adjunct for the treatment of depression; or if psychosis in patients with dementia has been treated for less than 3 months’ duration.

Methods

We used a comprehensive checklist for a successful guideline enterprise to develop the methods for the antipsychotic deprescribing guideline. The Guideline Development Team (GDT) comprised 9 clinicians (4 pharmacists [B.F., L.M., L.R.W., C.R.F.], 2 geriatricians [G.L., S.S.], 1 family physician [L.M.B.], 1 geriatric psychiatrist [A.W.], and 1 family physician specializing in LTC [L.G.]) and a Cochrane methodologist (V.W.). Expertise, role descriptions, and conflict of interest statements are available at CFPlus. We selected a guideline chair (L.M.B.) based on expertise in pharmacoepidemiology and in primary care clinical medicine. A Canadian Library of Family Medicine librarian conducted searches in collaboration with 1 staff member (M.H.).

We used the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system for guideline development (Box 1). We generated 2 clinical management questions using the PICO (population, intervention, comparison, outcome) approach: What are the effects (harm and benefits) associated with deprescribing compared with continuation of antipsychotic medication for the treatment of BPSD in adults, and what are the effects of continuing antipsychotic drugs for behavioural and psychological symptoms in older people with dementia?

The first question was addressed using the results of the 2013 Cochrane review “Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.” We communicated with the Managing Editor for
the Cochrane Dementia and Cognitive Improvement Group, who updated the search for this review in March of 2015, and concluded that no additional studies that met their inclusion criteria had been published since the 2013 review. Patient-important outcomes included the ability to successfully withdraw medication, a change in BPDS, the presence or absence of withdrawal symptoms, a change in the adverse effects of antipsychotics, a change in quality of life, and mortality. The results from individual studies for the outcomes of interest could not be pooled; thus, we produced a narrative summary of findings, which can be found at CFPPlus.

As there were no studies examining the deprescribing of antipsychotics used for the treatment of insomnia, we decided to focus on finding evidence for the effectiveness of such treatment. To answer our second PICO question, we conducted a systematic review to study the efficacy of antipsychotics for insomnia, focusing on patient-important outcomes such as total sleep time, latency to sleep, and sleep satisfaction.19,20

--- Recommendations ---

The recommendations are outlined in Box 2. The algorithm developed for this guideline is provided in Figure 1. The GRADE evidence tables used to evaluate the evidence for each patient-important outcome can be found at CFPPlus. The rationale for the recommendations is outlined in Table 1.18 The recommendations apply to adults who have been prescribed antipsychotics for insomnia or for BPDS, provided the symptoms of the latter are controlled or the patient is unresponsive to a reasonable trial of therapy. The evidence base for deprescribing relates mainly to patients with BPDS but can be extrapolated to those with insomnia or when short-term use is generally adequate (eg, transient delirium or psychosis unrelated to BPDS). The recommendations do not apply to those who have been prescribed antipsychotics for the treatment of disorders such as schizophrenia, schizoaffective disorder, bipolar disorder, acute delirium, Tourette syndrome or tic disorders, autism, mental retardation or developmental delay, obsessive-compulsive disorder, alcoholism, cocaine abuse, or Parkinson disease psychosis; or as an adjunct in the treatment of depression; or for the treatment of delusions and hallucinations in patients with dementia.

Box 1. Notes on the GRADE framework for guideline development

This guideline was developed in accordance with the methods proposed by the GRADE Working Group and was informed by a subset of data from an existing systematic review and by a new systematic review.19,20

• We focused our review and recommendations on outcomes important to patients, such as harms or benefits resulting from deprescribing antipsychotic medication.

• Outcomes were proposed by the team lead and guideline coordinator and were reviewed and approved by the Guideline Development Team.

• Ratings in the evidence profile tables included high, moderate, low, or very low and depended on our confidence in the estimates of effect. Because only randomized controlled trials were used, they started with a high quality rating, but could be rated down by limitations in any of 4 domains: risk of bias, inconsistency, indirectness, and imprecision. Other areas that were considered in formulating a final rating included harms, patient values and preferences, and resource use.

• The GRADE Working Group outlines appropriate wording for recommendations depending on the rating of strength and confidence in the evidence. A strong recommendation with implications for patients (phrased as “we recommend ...”) implies that all patients in the given situation would want the recommended course of action, and only a small proportion would not. A weak recommendation (phrased as “we suggest ...”) implies that most patients would wish to follow the recommendation, but some patients would not. Clinicians must help patients and caregivers make treatment decisions consistent with patients’ values and preferences. Implications for clinicians are similar such that a strong recommendation implies all or most patients should receive the intervention. A weak recommendation should prompt a clinician to recognize that different choices will be appropriate for individual patients.

Box 2. Recommendations for deprescribing antipsychotics

For adults with BPDS treated for at least 3 mo (symptoms stabilized or no response to adequate trial), we recommend the following:

• Taper and stop antipsychotics slowly in collaboration with the patient and caregivers: eg, 25%-50% dose reduction every 1-2 wk (strong recommendation, moderate-quality evidence)

For adults with primary insomnia treated for any duration or secondary insomnia in which underlying comorbidities are managed, we recommend the following:

• Stop antipsychotics; tapering is not needed (good practice recommendation)
Figure 1

Antipsychotic (AP) Deprescribing Algorithm

Why is patient taking an antipsychotic?

- Psychosis, aggression, agitation (behavioural and psychological symptoms of dementia - BPSD) treated ≥3 months (symptoms controlled, or no response to therapy).
- Primary insomnia treated for any duration or secondary insomnia where underlying comorbidities are managed.
- Schizophrenia
- Schizo-affective disorder
- Bipolar disorder
- Acute delirium
- Tourette’s syndrome
- Tic disorders
- Autism
- Less than 3 months duration of psychosis in dementia
- Mental retardation
- Developmental delay
- Obsessive-compulsive disorder
- Alcoholism
- Cocaine abuse
- Parkinson’s disease psychosis
- Adjunct for treatment of Major Depressive Disorder

Strong Recommendation (from Systematic Review and GRADE approach)

Taper and stop AP (slowly in collaboration with patient and/or caregiver; e.g. 25%-50% dose reduction every 1-2 weeks)

Stop AP
Good practice recommendation

Continue AP
or consult psychiatrist if considering deprescribing

Recommend Deprescribing

Expected benefits:
- May improve alertness, gait, reduce falls, or extrapyramidal symptoms

Adverse drug withdrawal events (closer monitoring for those with more severe baseline symptoms):
- Psychosis, aggression, agitation, delusions, hallucinations

Monitor every 1-2 weeks for duration of tapering

If BPSD relapses:
Consider:
- Non-drug approaches (e.g. music therapy, behavioural management strategies)

Restart AP drug:
- Restart AP at lowest dose possible if resurgence of BPSD with re-trial of deprescribing in 3 months
- At least 2 attempts to stop should be made

Alternate drugs:
- Consider change to risperidone, olanzapine, or aripiprazole

If insomnia relapses:
Consider:
- Minimize use of substances that worsen insomnia (e.g. caffeine, alcohol)
- Non-drug approaches (see reverse)

Alternate drugs:
- Other medications have been used to manage insomnia. Assessment of their safety and effectiveness is beyond the scope of this deprescribing algorithm. See AP deprescribing guideline for details.
Commonly Prescribed Antipsychotics

<table>
<thead>
<tr>
<th>Antipsychotic</th>
<th>Form</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chlorpromazine</td>
<td>T, IM, IV</td>
<td>25, 50, 100 mg/l25 mg/mL</td>
</tr>
<tr>
<td>Haloperidol (Haldol®)</td>
<td>T, L, IR, IM, IV LA</td>
<td>0.5, 1, 2, 5, 10, 20 mg 2 mg/mL  5 mg/mL  50, 100 mg/mL</td>
</tr>
<tr>
<td>Loxapine (Xyloc®)</td>
<td>T, L, IM</td>
<td>5, 20, 50 mg 25 mg/l 25, 50 mg/mL</td>
</tr>
<tr>
<td>Aripiprazole (Abilify®)</td>
<td>T, IM</td>
<td>2, 5, 10, 15, 20, 30 mg 300, 400 mg</td>
</tr>
<tr>
<td>Clozapine (Clozaril®)</td>
<td>T</td>
<td>25, 100 mg</td>
</tr>
<tr>
<td>Olanzapine (Zyprexa®)</td>
<td>T, D, IM</td>
<td>1.25, 2.5, 5, 7.5, 10, 15, 20 mg 5, 10, 15, 20 mg 10 mg per vial</td>
</tr>
<tr>
<td>Paliperidone (Invega®)</td>
<td>ER T, PR IM</td>
<td>2.5, 5, 7.5, 10, 15, 20 mg 10 mg per vial</td>
</tr>
<tr>
<td>Quetiapine (Seroquel®)</td>
<td>IRT, ER T</td>
<td>25, 100, 200, 300 mg 50, 150, 200, 300, 400 mg</td>
</tr>
<tr>
<td>Risperidone (Risperdal®)</td>
<td>T, S, D, PR IM</td>
<td>0.25, 0.5, 1, 2, 3, 4 mg 1 mg/mL  0.5, 1, 2, 3, 4 mg 10 mg/mL  15, 20, 25, 37.5, 50 mg</td>
</tr>
</tbody>
</table>

Antipsychotic side effects

- APs associated with increased risk of:
  - Metabolic disturbances, weight gain, dry mouth, dizziness
  - Somnolence, drowsiness, injury or falls, hip fractures, EPS, abnormal gait, urinary tract infections, cardiovascular adverse events, death
- Risk factors: higher dose, older age, Parkinson’s, Lewy Body Dementia

Engaging patients and caregivers

- Patients and caregivers should understand:
  - The rationale for deprescribing (risk of side effects of continued AP use)
  - Withdrawal symptoms, including BPSD symptom relapse, may occur
  - They are part of the tapering plan, and can control tapering rate and duration

Tapering doses

- No evidence that one tapering approach is better than another
- Consider:
  - Reduce to 75%, 50%, 25% of original dose on a weekly or bi-weekly basis and then stop; or
  - Consider slower tapering and frequent monitoring in those with severe baseline BPSD
  - Tapering may not be needed if low dose for insomnia only

Sleep management

- Primary care:
  1. Go to bed only when sleepy
  2. Do not use your bed or bedroom for anything but sleep (or intimacy)
  3. If you do not fall asleep within about 20-30 min at the beginning of the night or after an awakening, exit the bedroom
  4. If you do not fall asleep within 20-30 min on returning to bed, repeat #3
  5. Use your alarm to awaken at the same time every morning
  6. Do not nap
  7. Avoid caffeine after noon
  8. Avoid exercise, nicotine, alcohol, and big meals within 2 hrs of bedtime

- Institutional care:
  1. Pull up curtains during the day to obtain bright light exposure
  2. Keep alarm noises to a minimum
  3. Increase daytime activity and discourage daytime sleeping
  4. Reduce number of naps (no more than 30 mins and no naps after 2pm)
  5. Offer warm decaf drink, warm milk at night
  6. Restrict food, caffeine, smoking before bedtime
  7. Have the resident toilet before going to bed
  8. Encourage regular bedtimes and risings times
  9. Avoid waking at night to provide direct care
  10. Offer backrub, gentle massage

BPSD management

- Consider interventions such as: relaxation, social contact, sensory (music or aroma therapy), structured activities and behavioural therapy
- Address physical and other disease factors: e.g. pain, infection, constipation, depression
- Consider environment: e.g. light, noise
- Review medications that might be worsening symptoms

© Use freely, with credit to the authors. Not for commercial use. Do not modify or translate without permission.
Table 1. Evidence to recommendations table for deprescribing APs: Does deprescribing (dose reduction or frank discontinuation) APs compared with continuous AP use result in benefits or harms for adults > 18 y (excluding those prescribed APs for treatment of psychosis) in primary care and LTC settings?

<table>
<thead>
<tr>
<th>DECISION DOMAIN</th>
<th>SUMMARY OF REASON FOR DECISION</th>
<th>SUBDOMAINS INFLUENCING DECISION</th>
</tr>
</thead>
<tbody>
<tr>
<td>QoE: Is there high- or moderate-quality evidence?</td>
<td>The QoE for the success of deprescribing is high</td>
<td>The baseline symptom level might have an influence on the success of deprescribing APs. Patients with more severe baseline scores were more likely to experience relapses (defined as a 30% increase in the NPI score) in 2 studies. Withdrawal in patients with severe behavioural baseline scores might not be successful or should not be attempted.</td>
</tr>
<tr>
<td>Yes ☑ No □ (see references 1-10 in the evidence reviews at CFPlus*)</td>
<td>• High-quality evidence suggests that chronic AP medication can be withdrawn in many older people with Alzheimer dementia and NPS without detrimental effects on their behaviour and without substantial withdrawal symptoms</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• In terms of relapse (measured by a change in NPI score), there was no significant difference between people withdrawn from and those continuing APs at 3 mo (MD = -1.49, 95% CI -5.39 to 2.40)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>The QoE for effectiveness of atypical APs for insomnia is very low</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• One RCT (N = 13) demonstrated no statistical difference in total sleep time, onset of sleep latency, or sleep satisfaction for quetiapine vs placebo over 2 wk for primary insomnia. The trial was very low quality owing to imprecision and risk of bias</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Overall, benefits of AP deprescribing appear to outweigh harms</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Available evidence suggests that “many older people with Alzheimer’s dementia and NPS can be withdrawn from chronic antipsychotic medication without detrimental effects on their behaviour”18</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Effectiveness of atypical APs for insomnia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• There is very low certainty surrounding a lack of evidence that atypical APs are effective for managing insomnia (1 small RCT showing non-significant improvements in sleep parameters, and small uncontrolled trials). There is minimal information surrounding harms of atypical APs for insomnia; however, their use for other indications suggests potential for harm (eg, EPS, somnolence, metabolic disturbances, anticholinergic adverse effects)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• The magnitude of benefits of deprescribing in terms of cognition, psychomotor status, reductions in adverse effects of AP, or mortality are unclear. Declercq et al report that “Individual studies did not report significant differences between groups on any other outcome except one trial that found a significant difference in a measure of verbal fluency, favouring discontinuation. Most trials lacked power to detect clinically important differences between groups”16</td>
<td></td>
</tr>
<tr>
<td>Balance of benefits and harms: Is there certainty that the benefits outweigh the harms?</td>
<td>Is the baseline risk for benefit similar across subgroups? Yes ☑ No □</td>
<td></td>
</tr>
<tr>
<td>Yes ☑ No □ (see references 1-9 in the evidence reviews at CFPlus*)</td>
<td>Should there be separate recommendations for subgroups based on risk levels? Yes ☑ No □</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Is the baseline risk for harm similar across subgroups? Yes ☑ No □</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• There is insufficient evidence to assess any differences in risk of harm between groups. In patients with severe baseline BPSD, the likelihood of successfully deprescribing is probably lower; careful consideration should be given to plans for close monitoring and intervention if deprescribing is considered in these patients</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Should there be separate recommendations for subgroups based on harms? Yes ☑ No □</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• The main difference in the likelihood of benefiting from AP deprescribing relates to the baseline severity of BPSD. Declercq et al state that “Caution is required in older nursing home residents with more severe NPS, as two studies suggest these peoples’ symptoms might be worse if their [AP] medication is withdrawn”16</td>
<td></td>
</tr>
<tr>
<td>Values and preferences: Is there confidence in the estimate of relative importance of outcomes and patient preferences?</td>
<td>Reasons for prescribing APs include aggressive behaviour (physical and verbal), easier management of patients during daily care, as a sleep aid, or to help caregivers cope. Other viable options, such as nonpharmacologic alternatives, are less widely used owing to limited access, being highly resource dependent, and requiring additional staff training. APs can have a small effect in decreasing caregiver burden. Thus, there might be resistance from home-care staff when decreasing AP use or pressure from nursing home staff to prescribe APs. Inadequate staffing, additional workload, and increased demands are barriers to decreasing APs. Caregivers find the use of APs for controlling behaviour harmful. In addition, caregivers observe better patient QoL when APs are not used. Families would like more information on the side effects of APs</td>
<td></td>
</tr>
<tr>
<td>Yes ☑ No □</td>
<td>Perspective taken: the perspectives of the patient and caregivers are central to the decision to deprescribe APs, but so is the availability of professional health care support to monitor and accompany the process</td>
<td></td>
</tr>
<tr>
<td>Source of values and preferences: literature review, pilot study of guidelines in both LTC and outpatient settings</td>
<td>Source of variability, if any: variability difficult to estimate</td>
<td></td>
</tr>
<tr>
<td>Method for determining values satisfactory for this recommendation? Yes ☑ No □</td>
<td>All critical outcomes measured? Yes ☑ No □</td>
<td></td>
</tr>
<tr>
<td>• Although critical outcomes were assessed with a broad approach, evidence about cost implications of potential increases in caregiver burden could not be accurately quantified</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Continued on page 23
For patients stabilized for a minimum of 3 months on antipsychotic treatment for BPSD, gradual withdrawal of antipsychotics does not lead to worsening symptoms compared with those who continue taking antipsychotics. No consistent changes in cognition, mortality, or quality of life were observed, although 1 study found a significant decrease in mortality among those who discontinued antipsychotic treatment. A second small study found worsening of sleep efficiency in those who discontinued antipsychotic treatment; a second small study found worsening of sleep efficiency in those who had had antipsychotics withdrawn.

Table 1 outlines the evidence to recommendations considerations across all decision domains for deprescribing of antipsychotics in BPSD (quality of evidence, balance of benefits and harms, patient values and preferences, and resource implications). With regard to treatment of insomnia, only 1 small study (13 patients) was found; no results were statistically significant for benefit.

Based on the lack of evidence for the harm of deprescribing and the evidence for the benefit of reducing inappropriate antipsychotic use in terms of avoidance of the drug-related harms, the high societal cost of inappropriate antipsychotic use, the potential net cost benefit of switching to behavioural therapy, and the feasibility of an antipsychotic deprescribing intervention, we rated the recommendation to reduce or stop antipsychotic use for the treatment of BPSD as strong. Based on the lack of evidence for the efficacy of antipsychotics for treating insomnia, and the potential for harm and high cost, we rated the recommendation to eliminate antipsychotic use for the treatment of insomnia as strong.

Considerations of harms include the potential of well-known side effects (drowsiness, headache, extrapyramidal symptoms, weight gain, etc) and a heightened awareness of more serious adverse events, including a 1.5- to 2.0-fold increased risk of death and a 2.0-fold increased risk of cerebrovascular events. While the absolute risks of these serious adverse events are low and have not been confirmed in recent studies, they are serious enough to have prompted Health Canada to issue a warning. The ranges of frequency ratios of harms are available at CFPlus.*

With regard to values and preferences, some family members and front-line caregivers believe that the benefits of using antipsychotics for BPSD, including reducing caregiver burden, outweigh the risks of side effects despite an understanding of and concern about associated negative outcomes. However, others think those taking antipsychotics have a lower quality of life, and some will remove individuals from residential settings to reduce the risk that they will be prescribed antipsychotics. Providers, caregivers, and family members are aware of the difficulties in reducing antipsychotic use, including inadequate staffing, education, and resources for nonpharmacologic approaches. As treatment decisions are usually influenced by family expectations, attempts to withdraw antipsychotics should include their input. Evidence reviews and related references are available at CFPlus.*

In Canada, antipsychotic costs for seniors during the second quarter of 2014 reached $75 million. The rate of prescribing is 14 times higher in LTC facilities than in the community setting. Cost-effectiveness studies examining treatment options for BPSD show that behavioural interventions, such as cognitive stimulation therapy, are
projected to reduce costs, compared with antipsychotic use, from avoided falls and strokes and when quality-of-life improvements were considered. Antipsychotic use for treating BPSD has been shown to have a small but statistically significant effect on reducing caregiver burden, similar to the effects of support groups and psychoeducational interventions; however, the cost implications vary. Evidence reviews and related references can be found at CFPlus.

Clinical considerations
Combined with clinical judgment and an individualized approach to care, this guideline is intended to support clinicians and patients in successfully deprescribing antipsychotics, ultimately striving for better patient care.

The following questions were articulated by the GDT as being important to consider when making decisions about the steps for deprescribing antipsychotics.

Is there an indication and are there risk factors that warrant continued use? An important first step is to clarify when the antipsychotic was started and for what reason. This might require a chart review and discussion with the patient, caregivers, other prescribers (often other specialists), or pharmacist. If patients are using antipsychotics for insomnia, deprescribing is compelling, as there are no data to support antipsychotic use for this specific indication. Examples of patients in whom antipsychotics should be continued include those meeting exclusion criteria (eg, taking antipsychotics for psychosis), patients for whom repeated attempts have been made to deprescribe without success, and, in some cases, patients who recently started taking antipsychotics for BPSD and in whom it is too early to assess benefits and harms.

Guidelines such as those from the Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia suggest that risperidone, olanzapine, and aripiprazole should be considered for patients with severe agitation, aggression, and psychosis associated with dementia when there is risk of harm to the patient or others. However, research has demonstrated that antipsychotic medications have little to no effect on many BPSDs, such as wandering, hiding, hoarding, repetitive activities, vocally disruptive behaviour, and inappropriate dressing, and thus their use for such indications is inappropriate.

How should tapering be approached? Our literature review of antipsychotic deprescribing in BPSD did not identify trials that compared tapering approaches to minimize symptom recurrence. Of the studies included in the Cochrane review evaluating withdrawal of antipsychotics for BPSD, 7 studies used a taper strategy involving a 50% reduction in dosage per week over a period varying from 1 to 3 weeks, while 3 studies employed abrupt discontinuation. Clinicians at the LTC sites where this deprescribing guideline was piloted were not comfortable with what was perceived as rapid tapering in the Cochrane review; they preferred slower tapering, as reflected in Figure 1. However, they were comfortable with abrupt cessation when low-dose antipsychotics had been prescribed for insomnia. Tapering strategies are outlined in Box 3.

In all cases, regardless of the severity of BPSD or the use for insomnia, patient and caregiver involvement in the decision to deprescribe antipsychotics is essential. Good communication should include the rationale (eg, risk of side effects) and consideration of values and preferences, and should ensure understanding and agreement with the proposed changes (“buy-in”), as well as involvement in making the deprescribing and monitoring plans.

What monitoring needs to be done and how often? It is important to clarify with the patient, family, and health care staff what specific symptoms are being treated, what the desired response to treatment is, and the need to monitor the actual response following antipsychotic initiation and, likewise, discontinuation. This might require a retrospective chart review with the aim of documenting changes in the frequency or severity of target symptoms. It might be of value to use an objective measure such as the Neuropsychiatric Inventory (NPI) subscales or the behavioural subscales of

Box 3. Suggested tapering strategies

For those prescribed antipsychotics for the treatment of BPSD, we recommend considering the following:

- Reduce to 75%, 50%, and 25% of the original dose on a biweekly basis before stopping
- Alternatively, reduce the previous dose by approximately 50% every week down to 25% of the initial dose, then stop

In addition we recommend the following:

- For patients with severe baseline BPSD symptoms or long-standing use of antipsychotics, we recommend slower tapering, close monitoring for withdrawal symptoms, and establishing a clear intervention plan emphasizing the use of nonpharmacologic approaches first, in the event of increased severity or recurrence of neuropsychiatric symptoms
- Furthermore, tapering might need to be individualized depending on the starting dose, available dosage forms, and how tapering is tolerated

For those prescribed antipsychotics for the treatment of insomnia, we recommend the following:

- If the patient has been taking an antipsychotic for a short period of time (eg, < 6 wk), stop antipsychotic use immediately. If the patient has been taking the antipsychotic for a longer period of time, consider tapering the dose first before stopping. If there are concerns on the part of either the patient or the prescriber about possible side effects of immediate discontinuation, tapering can also be considered
- All patients should be counseled about nonpharmacologic approaches to sleep (so-called sleep hygiene)
the Resident Assessment Instrument–Minimum Data Set tool to quantify the frequency and severity of the symptoms at baseline and follow these parameters through time. Response can be defined as a decrease of 50% in the 3 target symptoms (psychosis, agitation, aggression).\textsuperscript{32} Physicians and caregivers should also monitor for expected benefits of deprescribing (such as reduced falls and improved cognition, alertness, function, extrapyramidal symptoms, and gait). Close monitoring (eg, every 1 to 2 weeks) is essential during the tapering process, and the use of objective measures can be helpful in identifying any behavioural recurrence or withdrawal symptoms, as well as the success of deprescribing.

Predictors of successful discontinuation of therapy include lower baseline severity of neuropsychiatric symptoms (NPI score < 15)\textsuperscript{33,34} and lower dosage of antipsychotic to achieve symptom control.\textsuperscript{22,35} Those receiving a higher dosage and those with higher NPI scores or higher global severity (as NPI or other tools are not commonly used) might require closer monitoring. Monitoring tools such as the Cohen-Mansfield Agitation Inventory, which is brief and easy to apply, might be more amenable to use for patients in LTC settings, where health care professionals are present.\textsuperscript{36,37} In the outpatient setting, family and caregiver involvement is key to monitoring behavioural recurrence, with close medical follow-up.

How should symptoms be managed? Nonpharmacologic approaches for insomnia (minimizing caffeine or alcohol that can worsen insomnia, or behavioural approaches) or other pharmacologic alternatives as suggested in contemporary sleep guidelines\textsuperscript{30,38,39} should be considered, keeping in mind that such guidelines are not specific to the geriatric population. Some of the recommended alternatives might not be appropriate for the elderly (eg, benzodiazepines, amitriptyline, zopiclone).\textsuperscript{40}

Nonpharmacologic approaches should be considered before pharmacologic approaches for management of BPSD when the situation is not urgent or when symptoms are not severe.\textsuperscript{29} These approaches could include social contact interventions, sensory or relaxation interventions (eg, music therapy, aromatherapy), structured activities, or behavioural therapy.\textsuperscript{29}

In patients whose BPSD recurs with discontinuation, addressing pain might be of value, as it is a common underlying cause of agitation in dementia; a recent randomized controlled trial in 352 patients reported a 17% improvement in agitation after stepped treatment with analgesics, similar to the benefit seen with antipsychotics.\textsuperscript{41} Further search for triggers and exacerbating factors including other diseases (eg, common viral illnesses, other infections), environmental causes (eg, new routine, relocation), physical problems (eg, constipation), other medications, and depression might also be of value.\textsuperscript{42} Such treatment is not a direct alternative to antipsychotics, but plays an important part in managing and preventing agitation and might reduce the need to restart antipsychotics. Realistically, some patients will not be successful with discontinuation; restarting an antipsychotic\textsuperscript{43} (eg, risperidone, olanzapine, aripiprazole)\textsuperscript{44} at the lowest dose possible can be done with retrial of discontinuation after 3 months.\textsuperscript{45}

Clinical and stakeholder review
External clinical review of the guideline was conducted by a pharmacist, a geriatrician, a family physician, and a nurse using the AGREE II (Appraisal of Guidelines for Research and Evaluation) Global Rating Scale tool.\textsuperscript{46} Relevant stakeholder organizations (eg, family practice, pharmacy, psychology, LTC) were invited to similarly review and endorse the guidelines (Box 4). Modifications were made to the original guideline draft to address reviewer comments.

How this deprescribing guideline relates to other clinical practice guidelines for antipsychotics
Existing clinical practice guidelines,\textsuperscript{43,47} including Canadian guidelines,\textsuperscript{29,49} as well as best-practice recommendations for older adults,\textsuperscript{50,48} consistently support the use of antipsychotics for BPSD only when patients are at risk of harming themselves or pose a considerable threat to others. In a 2012 systematic appraisal of guidelines for BPSD, Azermai et al reported that only 2 of the 15 evaluated guidelines addressed discontinuation of antipsychotics.\textsuperscript{49} Both recommended deprescribing after 3 to 6 months of behavioural stability.\textsuperscript{49} More recent guidelines\textsuperscript{49,47} or evidence-based updates to guidelines acknowledge that antipsychotics prescribed for the treatment of BPSD can be safely withdrawn in many patients, and discontinuation should be attempted when symptoms are stabilized.\textsuperscript{43} There is no information in current guidelines to assist physicians with deprescribing approaches (eg, tapering or abrupt cessation).

An antipsychotic deprescribing guideline supplements current treatment guidelines in offering clinicians recommendations and clinical considerations to support the deprescribing of antipsychotics after BPSD has been stabilized or following an appropriate trial without response to treatment.

Evidence-based and best-practice guidelines for treatment of insomnia recommend against using antipsychotics in all age groups, except when patients

**Box 4. Guideline endorsements**

This evidence-based clinical practice guideline for antipsychotics has been endorsed by the following groups:
- College of Family Physicians of Canada
- Canadian Pharmacists Association
- Canadian Society of Consultant Pharmacists
have comorbid insomnia related to conditions that are amenable to treatment with antipsychotics (eg, severe anxiety or bipolar disorder).38,39,48,50

Gaps in knowledge
Despite the widespread use of antipsychotics, numerous gaps in knowledge exist that could alter the strength of the recommendations in this guideline.

What are patients’ values and preferences regarding the use or deprescribing of antipsychotics for treating BPSD? Although there might be difficulties in obtaining reliable and usable data from this population, it is nonetheless a valuable perspective that should be included in weighing the benefits against the harms of using antipsychotics for BPSD. Such information would inform prescriber-patient-family discussions about BPSD treatment and deprescribing.

What are the indirect costs or cost savings associated with deprescribing antipsychotics for the treatment of BPSD? These indirect costs could result from changed caregiver requirements—either increased, if symptoms worsen, or decreased, if patients become more independent with activities of daily living—when a patient’s antipsychotic medication is reduced or discontinued.

In the case of the use of antipsychotics for treating insomnia, several additional pieces of evidence would have proven beneficial in weighing the benefits and harms of deprescribing. Are antipsychotics effective for treating insomnia? Only 1 study involving 13 participants was identified in the literature.23 Given that it showed modest but not statistically significant improvements in all 3 sleep outcomes, additional studies could strengthen the evidence for or against using antipsychotics for this purpose. What are the effects of deprescribing antipsychotics prescribed for the treatment of insomnia? Antipsychotics are generally taken at a lower dose for the treatment of insomnia than for other indications; however, the harms literature generally reports on antipsychotics used at higher doses. The adverse effect profile might not be the same in the case of insomnia.

What is the most effective strategy for tapering or stopping antipsychotics? Direct comparison of different deprescribing approaches would be helpful to determine if there is a best approach. This evidence would improve prescriber confidence in taking a patient off an antipsychotic.

Last, and falling outside the recommendations of this guideline, family physicians often see patients prescribed antipsychotics by psychiatrists for reasons other than BPSD or insomnia. Trials examining the outcomes of deprescribing antipsychotics for those with other conditions would prove beneficial to health care professionals weighing the harms and benefits of deprescribing in patients who might also be at higher risk of the adverse effects of continued antipsychotic treatment.

Next steps
The deprescribing team will endeavour to provide routine guideline updates as new evidence emerges that could change the recommendations. Prospective evaluation of the effects of the adoption of this and other deprescribing guidelines will be part of the research strategy in the future.

Conclusion
Overuse of medication is acknowledged to be a key contributor to polypharmacy, with attendant negative effects on health. Antipsychotics are increasingly used for indications for which they are not licensed or for which they have not been studied, such as BPSD and insomnia, yet their potential for harm with long-term use is well established. A systematic review identified that antipsychotics can be safely deprescribed in many patients with BPSD.18 Our systematic review of antipsychotic use in insomnia19,20 did not identify any studies of discontinuation that could inform our present guideline; however, we were also unable to find evidence supporting the use of antipsychotics for treating insomnia in the first place, suggesting that patients receiving antipsychotics for insomnia should have them stopped. When deprescribing antipsychotics, patient, family member, and caregiver involvement is crucial. The evidence, tapering strategies, and associated algorithm presented in this current guideline are intended to support this process.

This evidence-based guideline is one of a series of guidelines aimed at helping clinicians make decisions about when and how to safely stop medications. Implementation of such guidelines will encourage clinicians to carefully evaluate the ongoing use of medications and potentially reduce the negative effects of polypharmacy in the future.

Dr Bjerve is Assistant Professor in the Department of Family Medicine and in the School of Epidemiology and Public Health at the University of Ottawa in Ontario, Scientist in the C.T. Lamont Primary Health Care Research Centre of the Bruyère Research Institute, and Adjunct Scientist at the Institute for Clinical Evaluative Sciences (ICES). Dr Farrell is Assistant Professor in the Department of Family Medicine and in the School of Epidemiology and Public Health at the University of Ottawa, Adjunct Assistant Professor in the School of Pharmacy at the University of Waterloo in Ontario, and Scientist at the Bruyère Research Institute at the University of Ottawa. Dr Hogel was Research Associate at the Bruyère Research Institute at the time of guideline development. Dr Graham is Medical Director of St Patrick’s Home of Ottawa and Assistant Professor in the Department of Family Medicine at the University of Ottawa. Dr Lemay is Assistant Professor of Medicine at the University of Ottawa, Chief of Geriatric Services at Hôpital Montfort, and a staff geriatrician with the Ottawa Hospital Division of Geriatrics. Dr McCarthy is Scientist at the Women’s College Research Institute of Women’s College Hospital in Toronto, Ont, Assistant Professor with the Leslie Dan Faculty of Pharmacy and the Department of Family and Community Medicine at the University of Toronto. Dr Raman-Wilms was Associate Professor and Associate Dean of Professional Programs in the Leslie Dan Faculty of Pharmacy at the University of Toronto at the time of guideline development. Dr Rojas-Fernandez was Schlüegel Research Chair in Geriatric Pharmacotherapy at the School of Pharmacy and the School of Ageing Sciences (ICES). Dr Sinha is Director of Geriatrics at Mount Sinai Hospital and the University Health Network hospitals in Toronto, Assistant Professor in the Department of Medicine, the Department of Family and Community Medicine, and the Institute for Health Policy, Management and Evaluation at the University of Toronto, and Assistant Professor in the Division of Geriatric Medicine and Gerontology at the Johns Hopkins University School of Medicine in Baltimore, MD. Mr Thompson was a master’s student in the School of Epidemiology and Public Health at the University of Ottawa at the time of guideline development. Dr Welch was Director of the Methods Centre at the Bruyère Research Institute and Assistant Professor in the School of Epidemiology and Public Health at the University of Ottawa at the time of guideline development. Dr Wiens is Associate
Professor and Head of the Division of Geriatric Psychiatry in the Department of Psychiatry at the University of Ottawa.

Acknowledgment

For their clinical review of the guideline and invaluable feedback, we thank Allison Bell, a pharmacist with the Winnipeg Regional Health Authority in Manitoba; Dr David Straug, a geriatrician with the Winnipeg Regional Health Authority; Dr John Crosby, a pharmacist practicing in Cambridge, Ont; and Linda Hunter, former Chief Nursing Officer at Perley and Rideau Veterans’ Health Centre in Ottawa, Ont.

Contributors

All authors made substantial contributions to the conception and design of the guideline; the acquisition, analysis, and interpretation of data; and drafting the article, revising it critically for important intellectual content, and approving the final version.

Competing interests

Dr Farrell received research funding to develop this guideline; received financial payments from the Institute for Healthcare Improvement and Commonwealth Fund for a prescribing guidelines summary; and from the Ontario Long Term Care Physicians Association, the Ontario Pharmacists Association, and the Canadian Society of Hospital Pharmacists for speaking engagements. Dr Bjerre received a financial payment from the Ontario Long Term Care Physicians Association for a speaking engagement. None of the other authors has any competing interests to declare.

Correspondence

Dr Lise M. Bjerre; e-mail ljberre@bruerey.org

References

26. Rabins RV, Rovner BW, Rummans T, Schneider LS, Tariot PN. Antipsychotics in dementia: best practice guide

This article is eligible for Mainpro+ certified Self-Learning credits. To earn credits, go to www.cfp.ca and click on the Mainpro+ link.

This article has been peer reviewed. Can Fam Physician 2018;64:17-27

La traduction en français de cet article se trouve à www.cfp.ca dans la table des matières du numéro de janvier 2018 à la page e1.